KR102050100B1 - Composition for Preventing, Improving or Treating of muscular disease containing Phytolacca esculenta extract - Google Patents

Abstract

The present invention relates to a composition for preventing, improving or treating muscle diseases comprising a landing extract as an active ingredient, and more particularly, to a composition for strengthening muscles or a food composition for enhancing athletic performance, including a landing extract as an active ingredient. .
Since the method of the present invention has the effect of increasing the size of the muscle extract and improving the performance of exercise, it can be usefully used to prevent, improve or treat muscle diseases without side effects.

Description

Composition for Preventing, Improving or Treating muscular disease containing Phytolacca esculenta extract}

The present invention relates to a composition for preventing, improving or treating muscle diseases comprising a landing extract as an active ingredient, and more particularly, to a composition for strengthening muscles or a food composition for enhancing athletic performance, including a landing extract as an active ingredient. .

Muscle (Muscle) is the most constituent tissue in the human body to maintain the functional capacity of the human body (body), and to secure the appropriate muscle mass is necessary to prevent metabolic diseases. Muscle size is controlled by intracellular signaling pathways that induce anabolism or catabolism in muscle. If more signaling reactions that induce synthesis occur than muscle protein breakdown, muscle protein synthesis is increased, resulting in hypertrophy or hyperplasia, which increases muscle size. Journal of Sports Science, 20 (3): 1551-1561, 2011).

Muscles also boost calcium intake, increasing bone density. However, as the body ages, the redistribution of body fat and protein occurs as a result of changes in its composition.At 50 years of age, the synthesis rate of proteins in muscle cells is slower than the rate of decomposition, and muscles begin to degenerate rapidly. Can be.

Muscular dystrophy, one of the muscle-lowering diseases, refers to a condition in which about 13 to 24% of the usual body mass is reduced, indicating a decrease in protein content, fiber diameter, muscle strength production, and fatigue resistance. Muscle loss is caused by a variety of causes, including sepsis, cancer, renal failure, excess glucocorticoids, nerve loss, muscle inactivity and aging. This is mainly due to the gradual decrease in the amount and quality of skeletal muscle as aging progresses and the weight loss of fat and body fat due to inadequate dietary energy intake. .

Muscle loss occurs from the imbalance between protein synthesis and degradation. Muscle atrophy can significantly reduce the amount of behavior that not only hurts mental health, but also decreases the satisfaction of life.

Excessive exercise also causes muscle fatigue and damage and impairs athletic performance. Muscle injuries include bruises, lacerations, ischemia, strains and severe damage to skeletal muscles. Not only does this damage cause tremendous pain, but the injured person may not be able to continue exercising and working and may not even be able to perform normal daily activities, making him incompetent. If there is serious injury to skeletal muscle, the upper left is most common, and the upper left muscle is characterized by the destruction of the muscle-gun unit. This disruption of the muscle-gun unit can occur anywhere in the muscle. Restraints account for over 30% of all injuries treated professionally or by sports medicine professionals.

Treatments that can reduce muscle damage or speed up muscle tissue recovery are likely to speed up recovery of muscle strength after exercise. It may also help muscle recovery after a disease.

However, with the recent increase in interest in appearance and diet, muscle weight loss may be caused by rapid weight loss regardless of age, and violent exercise may damage muscles.

Accordingly, researches and efforts to treat or decrease muscles caused by general muscle reduction diseases have been concentrated, and there is still a need for research on the treatment and muscle strengthening of muscle reduction diseases.

Therefore, the present inventors have searched for natural substances that can enhance muscle function and inhibit muscle loss and can be safely applied. As a result, the landing extracts have the effect of preventing and treating myopathy, increasing muscle mass, inhibiting muscle loss, or increasing endurance. The present invention has been completed.

Therefore, the object of the present invention is to land ( Phytolacca esculenta ) to provide a composition for preventing, improving or treating muscle diseases comprising the extract as an active ingredient.

Another object of the present invention is to provide a composition for muscle strengthening comprising the landing extract as an active ingredient.

Still another object of the present invention is to provide a food composition for improving athletic performance, comprising a landing extract as an active ingredient.

In order to achieve the above object, the present invention is landing ( Phytolacca) esculenta ) provides a composition for preventing, improving or treating muscle diseases comprising the extract as an active ingredient.

In order to achieve the another object of the present invention, the present invention provides a composition for muscle strengthening comprising a landing extract as an active ingredient.

In order to achieve another object of the present invention, the present invention provides a food composition for improving athletic performance comprising the landing extract as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention is landing ( Phytolacca) esculenta ) provides a composition for preventing, improving or treating muscle diseases comprising the extract as an active ingredient.

In the present invention the landing ( Phytolacca esculenta ) 'refers to the root of periwinkle, also known as Dang (,), Chang-Lang (백), Baekchang (白 昌), Yaho (夜 呼), and is distributed in Korea, Japan and China. It contains a large amount of resin and salt, and also contains high glycosides, saponin and histamine. It has a diuretic effect, it is used to treat urinary symptoms, skin blisters (swellings), stomach and stomach fluids or gas in the abdomen, each, sore throat, malignant boils.

The extract of the present invention may be extracted by a known natural product extraction method. Although it has a meaning commonly used as a crude extract in the art, it broadly also includes a fraction additionally fractionating the extract. . That is, the landing extract includes not only one obtained by using an extraction solvent, but also one obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method may also be included in the extract of the present invention. Preferably it is an extract by at least one solvent selected from the group consisting of water, organic solvents having 1 to 6 carbon atoms, subcritical fluids, supercritical fluids and mixtures thereof.

In the present invention, the 'muscle disease' is a progressive disease characterized by loss of walking ability due to gradual decrease in muscle strength, weakening of respiratory strength, weakening of heart function, and eventually bringing a disorder of the body and leaving all daily life. It is a chronic disease that is relied upon. Muscle diseases may also be divided into congenital and acquired diseases, but are not limited thereto, but include, but are not limited to, atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscular dystrophy, muscular dystrophy, muscular dystrophy. Axon sclerosis, work sickness, cachexia or sarcopenia.

The present invention provides a composition for muscle strengthening comprising the landing extract as an active ingredient.

In the present invention, "muscle strengthening" refers to the effect of increasing the muscle strength and / or size of the muscle, and does not limit the type of muscle. Preferably, it exhibits the effect of increasing muscle mass and exhibits the effect of inhibiting muscle loss.

The increase in muscle mass is to improve the performance of the muscle, it is possible to increase the muscle mass through physical exercise and endurance improvement, it is possible to increase the muscle mass by administering a substance having a muscle increasing effect in the body. The muscle reduction is also characterized by a gradual loss of muscle mass, weakening and degeneration of muscles, particularly skeletal or veterinary and cardiac muscle, genetic factors, acquired factors. Aging may be the cause.

The composition of the present invention is characterized in that the pharmaceutical composition or food composition comprising a landing extract as an active ingredient.

The pharmaceutical compositions according to the invention may be formulated in a suitable form either alone or in combination with a pharmaceutically acceptable carrier, and may further contain excipients or diluents. As used herein, 'pharmaceutically acceptable' refers to a non-toxic composition that, when administered to human beings, is physiologically acceptable and typically does not cause allergic or similar reactions such as gastrointestinal disorders, dizziness, and the like.

Pharmaceutically acceptable carriers may further include, for example, carriers for oral administration or carriers for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. In addition, it may include a variety of drug delivery materials used for oral administration to the peptide formulation. In addition, carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycols, and the like, and may further include stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-parabens and chlorobutanol. The pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent and the like in addition to the above components. Other pharmaceutically acceptable carriers and formulations may be referred to as described in Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, PA, 1995.

The composition of the present invention may be administered to any mammal, including humans. For example, it can be administered orally or parenterally. Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration. Can be.

The pharmaceutical composition of the present invention may be formulated into a preparation for oral or parenteral administration according to the route of administration as described above.

In the case of preparations for oral administration, the compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions and the like. Can be. For example, oral formulations can be obtained by tablets or dragees by combining the active ingredients with solid excipients and then grinding them, adding suitable auxiliaries and processing them into granule mixtures. Examples of suitable excipients include sugars, including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol and starch, cellulose, including starch, corn starch, wheat starch, rice starch and potato starch, and the like. Fillers such as cellulose, gelatin, polyvinylpyrrolidone, and the like, including methyl cellulose, sodium carboxymethylcellulose, hydroxypropylmethyl-cellulose, and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid or sodium alginate and the like may optionally be added as a disintegrant. Furthermore, the pharmaceutical composition of the present invention may further include an anticoagulant, a lubricant, a humectant, a perfume, an emulsifier, a preservative, and the like.

Formulations for parenteral administration may be formulated by methods known in the art in the form of injections, creams, lotions, external ointments, oils, humectants, gels, aerosols and nasal inhalants. These formulations are described in Remington's Pharmaceutical Science, 19th ed., Mack Publishing Company, Easton, PA, 1995, a prescription generally known in all pharmaceutical chemistries.

 The total effective amount of the composition of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol which is administered in multiple doses for a long time. The pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the extent of the disease. Preferably the preferred total dose of the pharmaceutical composition of the present invention may be about 0.01 μg to 10,000 mg, most preferably 0.1 μg to 500 mg per kg of patient body weight per day. However, the dosage of the pharmaceutical composition is determined in consideration of various factors such as the formulation method, route of administration and frequency of treatment, as well as various factors such as the patient's age, weight, health status, sex, severity of the disease, diet and excretion rate. In view of this, one of ordinary skill in the art will be able to determine the appropriate effective dosage of the compositions of the present invention. The pharmaceutical composition according to the present invention is not particularly limited to its formulation, route of administration and method of administration as long as the effect of the present invention is shown.

The present invention provides a food composition for improving athletic performance comprising the landing extract as an active ingredient.

In the present invention, the 'exercise ability' is characterized by fast, strong, accurate, long, skillfully when the physical movements seen in everyday life or sports are divided into running, running, throwing, swimming, etc. The exercise performance is defined as factors such as muscle strength, agility and endurance.

The term 'enhancing athletic ability' refers to improving or improving athletic ability. Preferably, the food composition has an effect of increasing muscle strength and is characterized by an effect of increasing muscle endurance. In addition, it is not limited thereto, but may be to prevent or improve symptoms such as degenerative diseases, mitochondrial disorders, endurance, hypoplasia, lethargy, muscle atrophy, or depression.

The composition for food using the landing extract according to the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. These types can be prepared in various forms according to conventional methods known in the art.

For example, as a health food, the composition for food itself of the present invention can be prepared in the form of tea, juice and drink for drinking, or granulated, encapsulated and powdered. In addition, the food composition of the present invention may be prepared in the form of a composition by mixing with a known substance or active ingredient known to have the effect of promoting hair growth and anti-inflammatory.

Functional foods also include beverages (including alcoholic beverages), fruits and processed foods (e.g. canned fruit, canned foods, jams, marmalade, etc.), fish, meat and processed foods (e.g. hams, sausages and conveyors). If), breads and noodles (e.g. udon, soba, ramen, spaghetti, macaroni, etc.), fruit juices, various drinks, cookies, malts, dairy products (e.g. butter, cheese), edible vegetable oils, margarine It can be prepared by adding the food composition of the present invention to vegetable protein, retort food, frozen food, various seasonings (for example, miso, soy sauce, sauce, etc.).

The preferred content of the food composition according to the present invention is not limited thereto, but is preferably 0.01 to 50% by weight of the total weight of the finally prepared food. In order to use the food composition of the present invention in the form of a food additive, it may be prepared and used in powder or concentrate form.

In one embodiment of the present invention, after treating the landing extract to the muscle cells, when the MHC (myosin heavy chain) measured the fusion index (fusion index), when the landing extract is treated than the landing cells treated muscle extract In addition, it was confirmed that the binding index of MHC increases with concentration (see Example 1, Fig. 1).

In another embodiment of the present invention, after treating the landing extract to muscle cells, extracting RNA and measuring the amount of mRNA expression of MHC, the amount of MHC mRNA expression is greater than that of the case where the landing extract is not treated. It was confirmed that the increase, it was confirmed that the expression amount increases with the concentration (see Example 2, Figure 2).

In another embodiment of the present invention, after treating the TNF-α and the landing extract to the muscle cells, and observed the size of the cells under a microscope, when the TNF-α treatment, the size of the muscle cells, while landing When the extract was treated it was confirmed that the size of the muscle cells increased (see Example 3, Figure 3).

In another embodiment of the present invention, after feeding a diet containing a high-fat diet and a landing extract in a high-fat diet in a mouse, the result of measuring the maximum exercise performance by treadmill exercise method. Compared to the normal diet mice, the high-fat diet performance of the mice was reduced, and the high-fat diet mice administered the landing extract were confirmed to increase the maximum exercise performance according to the concentration of the landing extract (see Example 4, Figure 4).

In another embodiment of the present invention, after feeding a diet containing a high fat diet and a landing extract in a high fat diet in a mouse, taking muscle tissue at the expense of a mouse, extracting RNA from the muscle tissue, MyHC2b and Tropol As a result of measuring the expression level of the high-fat diet mice, when the landing extract was administered, it was confirmed that the expression level of MyHC2b was decreased compared to the control group (high-fat diet group, HFD), the expression level of Tropol increased compared to the control group It was confirmed (see Example 5, Fig. 5).

In another embodiment of the present invention, after feeding a diet containing a high-fat diet and a landing extract in a high-fat diet in a mouse, taking muscle tissue at the expense of a mouse, muscle gylcogen, which is a muscle marker of muscle As a result of measuring the enzymatic activity of muscle lactate, it was confirmed that the muscle glycogen activity decreased when the diet containing the landing extract in the high fat diet was decreased, and the activity of muscle lactate increased. (Example 6, see FIG. 6).

Accordingly, the present invention provides a composition for preventing, improving or treating muscle diseases, comprising a landing extract as an active ingredient. Since the method of the present invention has the effect of increasing the size of the muscle extract and improving the performance of exercise, it can be usefully used to prevent, improve or treat muscle diseases without side effects.

1 is a graph showing the binding index (fusion index) of the MHC (myosin heavy chain) according to the concentration when the landing extract treated muscle cells.
Figure 2 shows the results of measuring the expression level of the mRNA of MHC (myosin heavy chain) according to the concentration when the landing extract treated muscle cells.
Figure 3 shows the results of measuring the diameter of the cell according to the concentration when treated with TNF-α, and the landing extract to the muscle cells.
Figure 4 shows the results of evaluating the maximum exercise performance when the intake extract ingested in a high fat diet obesity induction model (NOR: normal diet group, HFD: high-fat diet group, PL: high-fat diet + landing extract (2.5%) , PH: high fat diet + land extract (5%)).
Figure 5 shows the results of measuring the expression level of muscle type mRNA (A: Tropol, B: MyHC2b when ingesting the landing extract in a high fat diet obesity induction model (NOR: normal diet group, HFD: high-fat diet group, PL: High fat diet + Land extract (2.5%), PH: High fat diet + Land extract (5%)).
Figure 6 shows the results of measuring the enzyme activity of muscle glycogen (A) and muscle lactate (B), the exercise markers of muscles when the intake extract ingested in a high fat diet obesity model (NOR: normal diet group, HFD: highland) DML: high fat diet + loose fern extract (2.5%), DMH: high fat diet + loose fern extract (5%)).
All studies were performed with one-way ANOVA using GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, USA), and statistical significance was verified by Boneferroni multiple comparison post test. * P <0.05, ** p It is indicated as <0.01, *** p <0.001.

Hereinafter, the present invention will be described in detail.

However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

<Example 1>

Effect of Aqueous Extract on MHC Binding of Muscle Cells

Landing ( Phytolacca esculenta ) extract was purchased from Korea Plant Extract Bank and used as a sample. Each sample is extracted with 95% ethanol or water.

First, mouse-derived myoblast C2C12 (CRL1772 ATCC, USA) cells were cultured in DMEM (Dulbecco's Modified Eagle Medium) medium containing 10% FBS, and at the initial stage of differentiation with differentiation medium (DMEM medium containing 2% HS) and Landing extracts were treated with 1, 5, 10 μg / mL. The cells were then fixed with 4% formaldehyde (formaldehyde) for 15 minutes at room temperature, then permeabilized with 0.05% saponin solution for 30 minutes at room temperature, and then blocked with 1% BSA solution for 1 hour. After reacting with a primary antibody (Total MyHC) for 1 hour at room temperature, washed with PBS to react the secondary fluorescent antibody in the same manner and then DAPI staining, and confirmed the root canal and nucleus by fluorescence microscope Image J was used to measure the number of nucleus in the root canal to determine the fusion index of the nucleus and muscle bundles.

As a result, as shown in Figure 1, when treated with the landing extract compared to the control (treated) without the landing extract, the binding index of the nucleus (nucleus) and muscle bundles (muscle bundle) appeared to be high, The binding index increased with concentration.

<Example 2>

Effect of Aqueous Extract on MHC Expression in Muscle Cells

After culturing the muscle cells, the landing extracts were treated with 1, 5, 10 μg / mL and incubated for 24 hours, and then washed with PBS to obtain the cells, and the cells were obtained according to the manufacturer's instructions. Total RNA was extracted using (Nacherey-Nagel, Duren, Germany). Then, cDNA was synthesized using a Synthesize cDNA for real-time PCR kit (ReverTra Ace qPCR RT Master Mix, FSQ-201, TOYOBO), and then synthesized into SYBR Green Master Mix (TOYOBO Co. Ltd., Osaka, Japan). PCR was performed to measure the mRNA expression level of MHC (myosin heavy chain).

As a result, as shown in Figure 2, when the landing extract was treated compared to the control (treated) not treated with the landing extract, the expression level of MHC mRNA appeared to increase, and the expression level of the mRNA increases with the concentration of the extract Appeared.

Primer Sequence Sequence SEQ ID NO: MyHC1 Sense CCA AGG GCC TGA ATG AGG AG One Anti-sense GTC CTG CAG CCT CAG CAC GTT 2 18s RNA Sense GTA ACC CGT TGA ACC CCA TT 3 Anti-sense CCA TCC AAT CGG TAG TAG CG 4

<Example 3>

Effect of Aqueous Extract on Muscle Cell Size

After culturing the muscle cells, TNF-α was treated with 25ng / mL, and the landing extract was treated with 1, 5, 10μg / mL and incubated for 24 hours. The size of the cells was then observed under a microscope, and the diameter of the cells was measured using the Image J program.

As a result, as shown in Figure 3, when treated with TNF-α, the diameter of the cell was reduced. When treated with the landing extract, the diameter of the cells appeared to increase.

<Example 4>

Effects of Landing Extracts on Exercise Performance

Eight-week-old male C57BL / 6 was used in this study after sufficient adaptation under certain conditions (temperature: 20 ± 2 ℃, humidity: 40-60%, contrast: 12 hours light / dark cycle) of animal history. Inducing obesity to a high fat diet of mice, an experimental diet containing landing extracts at concentrations of 2.5% and 5% was autonomous for 8 weeks, and all diets were prepared by the AIN 76 dietary composition.

Then, a treadmill exercise was performed at week 7 to confirm the improvement of the exercise performance of the mouse. The maximum exercise performance was measured by the distance (m) in which the mice were exhausted on a treadmill at a slope of 15 ° C. For treadmill exercise training, training was performed for 10 minutes at a speed of 5 m / min on the first day, 10 minutes at 10 m / min, 5 minutes at 5 m / min on the second day, and 15 minutes at 10 m / min. On the third day of the test, the speed was increased to 2 m / min every 2 minutes after 20 minutes of exercise at 10 m / min. Maximum exercise performance was converted to the distance run after stopping the exercise for 10 seconds or more on the grid.

As a result, as shown in Figure 4, compared to the normal diet (NOR) mice, high fat diet (high fat diet, HFD) was shown to decrease the maximum exercise performance, high-fat diet When one mouse was administered a landing extract (PL; high fat diet + 2.5% landing extract, PH; high fat diet + 5% landing extract), it was shown that the maximum exercise performance increased according to the administration concentration. In addition, when a high concentration of landing extract (PH), the normal diet was found to be almost similar to the maximum motor performance of the mouse.

Example 5

Effect of Aqueous Extract on Muscle Type mRNA Expression

Eight-week-old male C57BL / 6 was used in this study after sufficient adaptation under certain conditions (temperature: 20 ± 2 ℃, humidity: 40-60%, contrast: 12 hours light / dark cycle) of animal history. Inducing obesity to a high fat diet of mice, an experimental diet containing landing extracts at concentrations of 2.5% and 5% was autonomous for 8 weeks, and all diets were prepared by the AIN 76 dietary composition.

Next, a certain amount of muscle tissue (gastrocnemius and triceps) of the mouse was taken, total RNA was extracted using an RNA extraction kit according to the manufacturer's instructions, and cDNA was synthesized using Synthesize cDNA for real-time PCR kit, followed by SYBR. Real-time PCR analysis was performed using an Applied Biosystems 7900 HT thermal cycler (Applied Biosystems) using Green Master Mix (TOYOBO Co. Ltd., Osaka, Japan).

As a result, as shown in Figure 5, the expression level of MyHC2b increased in the high-fat diet group (HFD) compared to the normal diet group (NOR), the high-fat diet and landing extracts were fed to the feeding group (PL (2,5%), PH ( 5%))), the amount of expression was reduced (Fig. 5A). In addition, the expression of Tropol was decreased in the high-fat diet group (HFD) compared to the normal diet group (NOR), and the expression level was increased in the high-fat diet and the landing extract-treated group (PL (2,5%), PH (5%)). (FIG. 5B).

Primer Sequence Sequence SEQ ID NO: Myhc2b Sense CAC CTG GAG CGG ATG AAG AAG AAC 5 Anti-sense GTC CTG CAG CCT CAG CAC GTT 6 Tropol Sense ATG CCG GAA GTT GAG AGG AAA 7 Anti-sense TCC GAG AGG TAA CGC ACC TT 8 18s RNA Sense GTA ACC CGT TGA ACC CCA TT 3 Anti-sense CCA TCC AAT CGG TAG TAG CG 4

<Example 6>

Effect of Landing Extracts on Exercise Markers in Muscle

Eight-week-old male C57BL / 6 was used in this study after sufficient adaptation under certain conditions (temperature: 20 ± 2 ℃, humidity: 40-60%, contrast: 12 hours light / dark cycle) of animal history. Inducing obesity to a high fat diet of mice, an experimental diet containing landing extracts at concentrations of 2.5% and 5% was autonomous for 8 weeks, and all diets were prepared by the AIN 76 dietary composition.

Next, muscle glycogen and lactic acid activity were measured using an enzyme activity kit (Abcam, Cambridge, UK) according to the manufacturer's instructions.

As a result, as shown in Figure 6, compared with the normal diet group (NOR) high-fat diet group (HFD) increased muscle glycogen (muscle gylcogen) enzyme activity, high-fat diet and landing extract feeding group (PL (2,5%) ), PH (5%)) showed a decrease in muscle glycogen enzyme activity similar to the normal diet group (Fig. 6A). In addition, the enzyme activity of muscle lactate increased in the high-fat diet group (HFD) compared to the normal diet group (NOR), and the muscle in the landing extract supplement group (PL (2,5%), PH (5%)) Lactate enzymatic activity was found to decrease again (FIG. 6B).

As described above, the method of the present invention is effective in preventing, improving or treating muscle diseases without side effects, since the landing extract has the effect of increasing the size of muscle cells and improving the performance of exercise. Can be used.

<110> KOREA FOOD RESEARCH INSTITUTE <120> Composition for Preventing, Improving or Treating of muscular          disease containing Phytolacca esculenta extract <130> NP17-0116 <160> 8 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MyHC1 sense <400> 1 ccaagggcct gaatgaggag 20 <210> 2 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> MyHC1 anti-sense <400> 2 gtcctgcagc ctcagcacgt t 21 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 18s RNA sense <400> 3 gtaacccgtt gaaccccatt 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> 18s RNA anti-sense <400> 4 ccatccaatc ggtagtagcg 20 <210> 5 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> MyHC2b sense <400> 5 cacctggagc ggatgaagaa gaac 24 <210> 6 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> MyHC2b anti-sense <400> 6 gtcctgcagc ctcagcacgt t 21 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Tropol sense <400> 7 atgccggaag ttgagaggaa a 21 <210> 8 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tropol anti-sense <400> 8 tccgagaggt aacgcacctt 20

Claims (11)

Atony, muscular atrophy, muscular dystrophy, muscle degeneration, muscular dystrophy, muscular dystrophy, muscular atrophy, ataxia, cachexia, including Phytolacca esculenta extract ) And sarcopenia, wherein the pharmaceutical composition for preventing or treating muscle diseases is at least one selected from the group consisting of:
The composition of claim 1, wherein the extract is an extract by at least one solvent selected from the group consisting of water, an organic solvent having 1 to 6 carbon atoms, a subcritical fluid, a supercritical fluid, and mixtures thereof.
Atony, muscular atrophy, muscular dystrophy, muscular degeneration, muscular dystrophy, muscular dystrophy, muscular atrophy, ataxia, cachexia, including Phytolacca esculenta extract And one or more food composition for preventing or improving muscle diseases selected from the group consisting of sarcopenia.
A food composition for muscle strengthening comprising the landing extract as an active ingredient.
The composition of claim 4, wherein the composition has an effect of increasing muscle mass.
The composition of claim 4, wherein the composition has an effect of inhibiting muscle loss.
delete Food composition for improving athletic performance comprising the landing extract as an active ingredient.
The food composition of claim 8, wherein the food composition has an effect of increasing muscle strength.
The food composition of claim 8, wherein the food composition has an effect of increasing muscle endurance.
The food composition of claim 8, wherein the improvement of exercise ability is to prevent or ameliorate at least one symptom selected from the group consisting of degenerative disease, endurance, impairment, lethargy, and depression.

Images